Literature DB >> 16522790

Increasing importance of stem cell gene therapy in adenosine deaminase deficiency?

Oner Ozdemir.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16522790      PMCID： PMC1391970          DOI： 10.1128/CVI.13.3.433-435.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


× No keyword cloud information.
  17 in total

1.  Extreme thrombocytosis in response to PEG-ADA: early therapeutic and risk indicator.

Authors:  V R Marwaha; D H Italia; F Esper; R W Hostoffer
Journal:  Clin Pediatr (Phila)       Date:  2000-03       Impact factor: 1.168

2.  Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

Authors:  Belinda Chan; Diane Wara; John Bastian; Michael S Hershfield; John Bohnsack; Colleen G Azen; Robertson Parkman; Kenneth Weinberg; Donald B Kohn
Journal:  Clin Immunol       Date:  2005-08-22       Impact factor: 3.969

3.  Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients.

Authors:  Fabio Malacarne; Tiziana Benicchi; Lucia Dora Notarangelo; Luigi Mori; Silvia Parolini; Luigi Caimi; Michael Hershfield; Luigi Daniele Notarangelo; Luisa Imberti
Journal:  Eur J Immunol       Date:  2005-11       Impact factor: 5.532

4.  polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayed-onset ADA deficiency.

Authors:  Elke Lainka; Michael S Hershfield; Ines Santisteban; Pawan Bali; Annette Seibt; Jennifer Neubert; Wilhelm Friedrich; Tim Niehues
Journal:  Clin Diagn Lab Immunol       Date:  2005-07

5.  The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities.

Authors:  M R Blackburn; M Aldrich; J B Volmer; W Chen; H Zhong; S Kelly; M S Hershfield; S K Datta; R E Kellems
Journal:  J Biol Chem       Date:  2000-10-13       Impact factor: 5.157

Review 6.  [Gene therapy for adenosine deaminase deficiency].

Authors:  Yukio Sakiyama; Tadashi Ariga; Makoto Ohtsu
Journal:  Nihon Rinsho       Date:  2005-03

7.  Anti-adenosine deaminase antibodies in lupus erythematosus.

Authors:  J Y Y Lee; J Hempel; J S Deng
Journal:  Lupus       Date:  2002       Impact factor: 2.911

8.  Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase.

Authors:  David A Kaufman; Michael S Hershfield; Joseph A Bocchini; I John Moissidis; Majed Jeroudi; Sami L Bahna
Journal:  Pediatrics       Date:  2005-11-01       Impact factor: 7.124

Review 9.  Perspectives of gene therapy for primary immunodeficiencies.

Authors:  Javier Chinen; Jennifer M Puck
Journal:  Curr Opin Allergy Clin Immunol       Date:  2004-12

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.